Holen Sie sich die Stockscreener-App
53.27
0.84%
-0.45
Handel nachbörslich:
53.27
Schlusskurs vom Vortag:
$53.72
Offen:
$53.63
24-Stunden-Volumen:
474.83K
Relative Volume:
0.72
Marktkapitalisierung:
$2.91B
Einnahmen:
$1.28B
Nettoeinkommen (Verlust:
$-222.15M
KGV:
-13.02
EPS:
-4.09
Netto-Cashflow:
$145.52M
1W Leistung:
+7.49%
1M Leistung:
+26.89%
6M Leistung:
+12.84%
1J Leistung:
+15.70%
1-Tages-Spanne:
$52.95
$53.98
1-Wochen-Bereich:
$49.77
$54.72
52-Wochen-Spanne:
$32.48
$57.35
Livanova Plc Stock (LIVN) Company Profile
Firmenname
Livanova Plc
Sektor
Branche
Telefon
4402033250662
Adresse
20 EASTBOURNE TERRACE, LONDON
Vergleichen Sie LIVN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LIVN
Livanova Plc
|
53.27 | 2.93B | 1.28B | -222.15M | 145.52M | -4.09 |
|
ABT
Abbott Laboratories
|
130.27 | 229.31B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
103.05 | 152.87B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
381.61 | 146.01B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.81 | 119.18B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
78.30 | 45.95B | 5.69B | 1.41B | 577.90M | 6.95 |
Livanova Plc Stock (LIVN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-20 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2025-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-10-04 | Eingeleitet | Goldman | Buy |
| 2024-09-17 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2024-03-20 | Bestätigt | Needham | Buy |
| 2024-02-20 | Hochstufung | Mizuho | Neutral → Buy |
| 2023-09-06 | Eingeleitet | HSBC Securities | Hold |
| 2023-07-19 | Eingeleitet | Robert W. Baird | Neutral |
| 2023-04-14 | Eingeleitet | Mizuho | Neutral |
| 2022-12-21 | Eingeleitet | Barclays | Equal Weight |
| 2022-04-06 | Eingeleitet | Wolfe Research | Outperform |
| 2022-02-24 | Hochstufung | UBS | Neutral → Buy |
| 2021-12-03 | Eingeleitet | Goldman | Buy |
| 2021-08-20 | Bestätigt | Needham | Buy |
| 2021-07-20 | Hochstufung | Needham | Hold → Buy |
| 2021-03-03 | Herabstufung | Berenberg | Buy → Hold |
| 2021-01-05 | Herabstufung | Needham | Buy → Hold |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Outperform |
| 2020-06-26 | Bestätigt | Needham | Buy |
| 2019-10-30 | Bestätigt | Needham | Buy |
| 2019-02-28 | Bestätigt | Needham | Buy |
| 2018-11-28 | Eingeleitet | UBS | Neutral |
| 2018-08-02 | Bestätigt | Needham | Buy |
| 2018-06-08 | Eingeleitet | Stifel | Buy |
| 2018-05-31 | Bestätigt | Needham | Buy |
| 2018-02-28 | Bestätigt | Needham | Buy |
Alle ansehen
Livanova Plc Aktie (LIVN) Neueste Nachrichten
LivaNova’s Essenz perfusion system launches in China - Investing.com
LivaNova's Expansion in China with the Essenz Perfusion System: A Strategic Catalyst for Growth in a High-Potential Market - AInvest
LivaNova Launches Essenz Perfusion System in China - Eagle-Tribune
Should value investors consider LivaNova PLCJuly 2025 News Drivers & Low Risk Profit Maximizing Plans - thegnnews.com
Optimistic Investors Push LivaNova PLC (NASDAQ:LIVN) Shares Up 28% But Growth Is Lacking - simplywall.st
Bollinger Band Squeeze Points to Volatility in LivaNova PLCJuly 2025 News Drivers & Low Volatility Stock Suggestions - beatles.ru
What earnings revisions data tells us about LivaNova PLCMarket Volume Summary & AI Driven Stock Movement Reports - Newser
LivaNova PLC Enters Reversal Setup in Weekly ChartsJuly 2025 Technicals & Capital Protection Trade Alerts - beatles.ru
Sentiment analysis tools applied to LivaNova PLCPortfolio Value Summary & Fast Exit and Entry Strategy Plans - Newser
Why LivaNova (LIVN) Is Up 12.0% After Strong Q2 Results and Raised 2025 Revenue Guidance - simplywall.st
LivaNova PLC stock trend forecast2025 Price Targets & Long-Term Capital Growth Strategies - Newser
Machine Learning Models Forecast LivaNova PLC UptickWeekly Trend Report & Low Risk Entry Point Guides - sundaytimes.kr
Visual trend scoring systems applied to LivaNova PLC [Quarterly Trade Review]Free Risk Managed Investment Strategies - Newser
Chart based exit strategy for LivaNova PLCFree Capital Preserving Trade Plan Templates - Newser
Single-Chamber Pacemaker Market to Reach $2.77 Billion by 2031, - openPR.com
What recovery options are there for LivaNova PLCRisk/Reward Optimization Entry Point Analysis - Newser
LivaNova (LIVN) Is Up 18.7% After Strong Q2 Results and Raised 2025 Guidance – What's Changed - simplywall.st
Jefferies Reaffirms ‘Buy’ Rating on LivaNova PLC (LIVN) with $79 PT - MSN
How hedge fund analytics apply to LivaNova PLC stockAI Intraday Market Movement Prediction Tool - Newser
LivaNova PLC (NASDAQ:LIVN) Receives Average Recommendation of “Buy” from Analysts - Defense World
Can machine learning forecast LivaNova PLC recoveryFree Trade Ready Stock Watch for Short Term - Newser
LivaNova (NASDAQ:LIVN) Upgraded by Wall Street Zen to “Strong-Buy” Rating - Defense World
LivaNova PLC Company Revenue and Profit Trends: A Deep DiveSmart Risk Strategy with Entry Optimization - Newser
Real time scanner hits for LivaNova PLC explainedInvestment Position Summary with Timeframe Forecast - Newser
LivaNova PLC Reports Strong Q2 Earnings and Raised Guidance - The Globe and Mail
LivaNova (LIVN) Is Up 18.0% After Raising 2025 Outlook and Advancing Core Technology Platforms - simplywall.st
LivaNova PLC (NASDAQ:LIVN) Q2 2025 Earnings Call Transcript - Insider Monkey
Goldman Sachs raises Livanova stock price target to $168 on strong 2Q25 - Investing.com Nigeria
LivaNova Reports Strong Q2 2025 Revenue Growth, Raises Full-Year Guidance - AInvest
LivaNova raises 2025 organic growth outlook to 9%-10% with upgraded guidance for cardiopulmonary and epilepsy - MSN
Livanova stock price target raised to $65 from $55 at Mizuho - Investing.com Canada
LIVN Stock Price and Chart — NASDAQ:LIVN - TradingView
LivaNova Q2 2025 revenue increased 10.7% to USD 352.5M - Medical Buyer
Decoding LivaNova PLC (LIVN): A Strategic SWOT Insight - GuruFocus
LivaNova: Q2 Earnings Snapshot - Connecticut Post
LivaNova PLC Reports Strong Q2 2025 Results - TipRanks
LivaNova PLC (LIVN): Accelerating Growth in Neuromodulation and Cardiopulmonary Markets - AInvest
LivaNova Earnings: Strength in Cardiopulmonary Fuels Strong Second Quarter - Morningstar
LivaNova Has Found New Opportunities for Innovation in Its Strongholds - Morningstar
LivaNova Q2 2025 Earnings Call Transcript - MarketBeat
Transcript : LivaNova PLC, Q2 2025 Earnings Call, Aug 06, 2025 - MarketScreener
LivaNova stock rises before hours on Q2 beats, raised guidance - MassDevice
LivaNova PLC reports results for the quarter ended June 30Earnings Summary - TradingView
LivaNova Exceeds Q2 Earnings Expectations with Robust GrowthNews and Statistics - IndexBox
LivaNova (LIVN) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
LivaNova's Outperformance and Strategic Momentum in 2025: Why Revenue, Margin Expansion, and Clinical Innovation Justify a Buy Now Position in Medical Tech - AInvest
LIVN Forecasts Higher Revenue Growth for 2025 - GuruFocus
LivaNova Q2 Adjusted Earnings, Revenue Rise; Raises 2025 Adjusted Earnings Guidance - MarketScreener
LivaNova PLC Q2 2025 Earnings: EPS of $1.05 Beats Estimate, Reve - GuruFocus
LivaNova PLC earnings beat by $0.18, revenue topped estimates - Investing.com
LivaNova results exceed second-quarter expectations - Investing.com India
Finanzdaten der Livanova Plc-Aktie (LIVN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Livanova Plc-Aktie (LIVN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Bianchi Francesco | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
10,938 |
| SCHERMERHORN TODD C | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
9,473 |
| KOZY WILLIAM A | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
4,840 |
0 |
33,148 |
| Barry James Christopher | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
4,772 |
| Story Brooke | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
6,892 |
| Enxing Seng Stacy | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
12,161 |
| WILVER PETER M | Director |
Jun 15 '25 |
Option Exercise |
0.00 |
3,416 |
0 |
7,148 |
| Tezel Ahmet | Chief Innovation Officer |
Jun 15 '25 |
Option Exercise |
0.00 |
2,967 |
0 |
2,967 |
| Bolton Stephanie | President, Global Epilepsy |
Mar 30 '25 |
Option Exercise |
0.00 |
6,024 |
0 |
15,586 |
| Makatsaria Vladimir | Chief Executive Officer |
Mar 30 '25 |
Option Exercise |
0.00 |
9,330 |
0 |
9,330 |
0.56%
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):